Evidence map›Paper›PMID 38876199›Full record

ArticleHuman pathology2024

Steatohepatitic hepatocellular Carcinoma:A new approach to classifying morphological subtypes of hepatocellular carcinoma.

Gwyneth S T Soon, Francesco Callea, Alastair D Burt, Sam Cook, Luigi Terracciano, Caner Ercan, Hans-Peter Dienes, Zachary D Goodman, Eve A Roberts, Andrew D Clouston and 10 more

Abstract read
In one paragraph

Article in Human pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Gwyneth S T SoonDepartment of Pathology, National University Hospital, Singapore.
Francesco CalleaOspedale Pediatrico Bambino Gesu, 00165 Rome, Italy.
Alastair D BurtTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Sam CookTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Luigi TerraccianoDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
Caner ErcanInstitute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.
Hans-Peter DienesInstitute of Pathology, Meduniwien, Medical University of Vienna, 1090 Wien, Austria.
Zachary D GoodmanCenter for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA.
Eve A RobertsDivision of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario M5G1X8, Canada.
Andrew D CloustonCentre for Liver Disease Research, School of Medicine (Southern), University of Queensland, Princess Alexandra Hospital, Ipswich Rd Woolloongabba 4109, Australia.
Annette S H GouwDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9700 RB Groningen, the Netherlands.
David E KleinerLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Young Nyun ParkDepartment of Pathology, Yonsei University College of Medicine, Seoul Korea.
Taek ChungDepartment of Pathology, Yonsei University College of Medicine, Seoul Korea. Electronic address: jtaek0517@yuhs.ac.
Peter SchirmacherInstitute of Pathology, University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Dina TiniakosTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom; Department of Pathology, Aretaieion Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
Konstantina DimopoulouDepartment of Pathology, Aretaieion Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
Achim WeberDepartment of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Katharina EndhardtDepartment of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Michael TorbensonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Torbenson.Michael@mayo.edu.

Funding

Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
NCI NIH HHS P50 CA210964
6 · The paper itself

Abstract

Histological subtyping of hepatocellular carcinoma (HCC) is challenging in the presence of histological heterogeneity, where distinctly different morphological patterns are present within the same tumor. Current approaches rely on percent cut-offs. We hypothesized that morphologic intratumor heterogeneity is a non-random biological feature and that incorporating recurrent patterns would improve histological subtyping of HCC. Resected HCC were studied and the overall frequency of morphologic intratumor heterogeneity was 45% in 242 specimens. Steatohepatitic HCC (SH-HCC) had the highest frequency of morphologic intratumor heterogeneity (91%); this was confirmed in additional cohorts of SH-HCC from different medical centers (overall frequency of 78% in SH-HCC). Morphologic intratumor heterogeneity in SH-HCC showed distinct and recurrent patterns that could be classified as early, intermediate, and advanced. Incorporating these patterns into the definition of SH-HCC allowed successful resolution of several persistent challenges: the problem of the best cut-off for subtyping SH-HCC, the problem of the relationship between SH-HCC and scirrhous HCC, and the classification for HCC with abundant microvesicular steatosis. This approach also clarified the relationship between SH-HCC and CTNNB1 mutations, showing that CTNNB1 mutations occur late in a subset of SH-HCC. In summary, there is a high frequency of morphologic intratumor heterogeneity in HCC. Incorporating this finding into histological subtyping resolved several persistent problems with the SH-HCC subtype.

Indexed as

beta CateninCarcinoma, HepatocellularFatty LiverLiver NeoplasmsMutationAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle Agedbeta CateninBiomarkers, TumorCTNNB1 protein, human

Identifiers

PMID38876199
PMCPMC12236939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.